US FDA’s Median Review Time Remains Less Than One Year Despite Swell Of Missed Goal Dates

 
• By Bridget Silverman
  
Pink Sheet Perspectives
The US FDA stayed on top of review times for novel agents in 2024, keeping close to PDUFA timetables. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pink Sheet Perspectives

More from Regulatory Trackers